[EN] HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOQUINOLINONE SUBSTITUÉS PAR UN HYDROXY
申请人:NOVARTIS AG
公开号:WO2012175520A1
公开(公告)日:2012-12-27
The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
Studies on enolate chemistry of 8-thiabicyclo[3.2.1]- octan-3-one: enantioselective deprotonation and synthesis of sulfur analogs of tropane alkaloids
作者:Marek Majewski、Marc DeCaire、Pawel Nowak、Fan Wang
DOI:10.1139/v01-157
日期:2001.11.1
Enantioselective deprotonation of 8-thiabicyclo[3.2.1]octan-3-one (1) with chiral lithium amides, followed by reactions with electrophiles affords sulfur analogs of tropane alkaloids of pyranotropa...
Sulfide extrusion from the methylsulfonium salts of 8-thiabicyclo [3.2.1]oct-2-enes and the related sulfonium salts by methyllithium
作者:Tadao Uyehara、Masayuki Takahashi、Tadahiro Kato
DOI:10.1016/0040-4039(84)80050-7
日期:——
The methysulfonium salts of 2-methylene-8-thiabicyclo[3.2.1]octane and 8-thiabicyclo[3.2.1]oct-2-enes underwent sulfideextrusion by methyllithium to give dimethyl sulfide and the hydrogen shift products (cycloheptadienes) and/or the closure products (bicycloheptenes).
The photoreactivity of 9-thiabicyclo[3.3.1]nonan-3-one 9 is investigated under a variety of conditions and compared with those of its monocyclic or norbicyclic analogues 1 and 4. The principal reaction of ketone 9 on irradiation in tert-butyl alcohol is the Norrish type I cleavage to yield tert-butyl (cis-6-methyltetrahydrothiopyran-2-yl)acetate 10a, while compounds 1 and 4 give ring-contracted thilactones
Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
申请人:Guyaux Michel
公开号:US20050020660A1
公开(公告)日:2005-01-27
The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention_show high affinities for m3 and/or m2 muscarinic receptors and are particularly suited for treating urinary incontinence.